Published Studies Related to Timoptic-XE (Timolol Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. 
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial. 
(length 4 to 8) was used for treatment allocation... CONCLUSIONS: Timolol application is effective for the treatment of myopic
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. [2011.06]
CONCLUSION: MK-0507A has a significantly superior IOP-lowering effect relative to timolol. MK-0507A also showed a non-inferior IOP-lowering effect relative to the concomitant therapy. MK-0507A was safe compared to both timolol and concomitant therapy.
Clinical Trials Related to Timoptic-XE (Timolol Ophthalmic)
Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma [Recruiting]
Topical Timolol Gel for the Treatment of Infantile Hemangiomas [Not yet recruiting]
We plan to conduct a study, to see how safe and effective timolol maleate 0. 5% gel is for
hemangiomas of infancy (HOI) and the response of hemangiomas to timolol maleate 0. 5% versus
a control solution. Our hypothesis is that timolol will inhibit and possibly reverse growth
of appropriate infantile hemangiomas as compared to a control solution.
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) [Withdrawn]
The purpose of this study is to determine whether Timolol 0. 5% Gel Forming Solution is safe
and effective in promoting wound healing of infantile ulcerated hemangiomas compared with
standard conservative management with topical antibiotic.
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients [Completed]
The purpose of this study is to demonstrate that fixed combination of latanoprost and
timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5% [Withdrawn]
The purpose of this study is to evaluate the feasibility of rapid evaluation and
administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior
ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the
progression or improves recovery of patients who are randomly assigned to treatment versus
standard of care.